# Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

> **NCT03547271** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1660 (actual)

## Conditions studied

- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** MenACYW conjugate vaccine
- **BIOLOGICAL:** Meningococcal group A, C, W-135, and Y conjugate vaccine
- **BIOLOGICAL:** DTaP-IPV-HB-Hib vaccine
- **BIOLOGICAL:** Pneumococcal vaccine (13-valent)
- **BIOLOGICAL:** Pneumococcal vaccine (10-valent)
- **BIOLOGICAL:** MMR vaccine

## Key facts

- **NCT ID:** NCT03547271
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-14
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-24
- **Target enrollment:** 1660 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547271, "Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03547271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*